Claims for Patent: 9,107,906

Summary for Patent: 9,107,906

Title:	Compositions and methods for the treatment of immunodeficiency
Abstract:	The present invention relates to compositions and methods for the treatment of immunodeficiency (e.g., primary immunodeficiency disease). In particular, the invention provides human plasma immunoglobulin compositions containing select antibody titers specific for a plurality of respiratory pathogens, methods of identifying human donors and donor samples for use in the compositions, methods of manufacturing the compositions, and methods of utilizing the compositions (e.g., for prophylactic administration and/or therapeutic treatment (e.g., passive immunization (e.g., immune-prophylaxis))).
Inventor(s):	Grossman; Adam S. (Saddle River, NJ), Mond; James (Silver Spring, MD), Grossman; Jerrold B. (Saddle River, NJ)
Assignee:	ADMA BIOLOGICS, INC. (Ramsey, NJ)
Application Number:	14/592,721
Patent Claims:	1. A method of producing a pooled plasma composition containing an elevated titer of respiratory syncytial virus (RSV) neutralizing antibodies and antibodies directed against one or more other respiratory pathogens comprising: 1) conducting a first assay to measure RSV neutralizing activity of plasma from individual human donors; 2) from donors demonstrating RSV neutralizing activity in the top 20% of the assayed population, purifying an immunoglobulin fraction and conducting an RSV titration curve measuring the RSV neutralizing titer of the immunoglobulin fraction, wherein donors with an immunoglobulin fraction RSV neutralizing titer of 1800 or above are categorized as high titer selected human donors; and 3) pooling plasma from 1000 or more donors including high titer selected human donors categorized according to step 2, wherein less than 50% of the donors are high titer selected human donors, such that the resultant pooled plasma comprises a titer of RSV neutralizing antibodies that is at least 3 times greater than the titer of RSV neutralizing antibodies in a control sample, and an antibody titer for one or more respiratory pathogens selected from parainfluenza virus 1, parainfluenza virus 2, coronavirus OC43 and coronavirus 229E that is at least 1.5 times greater than the antibody titer in the control sample, wherein the control sample is a mixture of plasma samples obtained from 1000 or more random human plasma donors. 2. The method of claim 1, wherein the plasma is screened in order to confirm the absence of one or more bloodborne pathogens. 3. The method of claim 2, wherein the plasma is screened before and/or after pooling. 4. The method of claim 1, wherein 35-45% of the donors are high titer selected human donors. 5. The method of claim 1, wherein the pooled plasma composition comprises plasma from 1000-1100 human donors. 6. The method of claim 1, further comprising assaying the pooled plasma composition for antibody titers to measles virus, Corynebacterium diphtheria, and polio virus. 7. The method of claim 1, further comprising 4) preparing immunoglobulin from the plasma pooled according to step 3). 8. The method of claim 7, wherein immunoglobulin is prepared using a cold alcohol fractionation process that isolates the immune globulin fraction from the pooled plasma as a solution.

Details for Patent 9,107,906

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Adma Biologics, Inc.	NABI-HB	hepatitis b immune globulin (human)	Injection	103945	October 23, 2001	9,107,906	2035-01-08
Octapharma Pharmazeutika Produktionsges.m.b.h.	OCTAGAM	immune globulin intravenous (human)	Injection	125062	May 21, 2004	9,107,906	2035-01-08
Octapharma Pharmazeutika Produktionsges.m.b.h.	OCTAGAM	immune globulin intravenous (human)	Injection	125062	March 26, 2007	9,107,906	2035-01-08
Octapharma Pharmazeutika Produktionsges.m.b.h.	OCTAGAM	immune globulin intravenous (human)	Injection	125062	July 11, 2014	9,107,906	2035-01-08
Adma Biologics, Inc.	BIVIGAM	immune globulin intravenous (human)	Injection	125389	December 19, 2012	9,107,906	2035-01-08

International Patent Family for US Patent 9,107,906

Country	Patent Number	Estimated Expiration
South Africa	201707303
World Intellectual Property Organization (WIPO)	2016069693
United States of America	9969793
United States of America	9815886
United States of America	9714283